# Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

> **NCT00304083** · PHASE2 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 48 (actual)

## Conditions studied

- Neurofibromatosis Type 1
- Sarcoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **PROCEDURE:** conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00304083
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304083, "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00304083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*